Fidelity Investments slashes Juul Labs' valuation in Q2

Fidelity Investments has significantly lowered the valuation of Juul Labs Inc. in the second quarter due to concerns over the U.S. crackdown on e-cigarettes.

According to data analysis collected by Bloomberg, asset management companies reported that their funds have reduced Juul's valuation by approximately 88%. The data shows that as of June 30th, Fidelity Funds lowered Juul's per share price from $41.01 on March 31st to $4.86, while during the same period, a capital group fund reduced the closely held company's stock price from $52.40 to $6.46.

These cuts have resulted in a series of write-downs for investors as the company undergoes FDA review. Altria Group Inc., the maker of Marlboro cigarettes, spent $12.8 billion in 2018 to acquire a 35% stake in Juul, but as of June 30th, their investment was only worth $450 million. According to PitchBook data, Tiger Global Management and Darsana Capital Partners have also invested in Juul, as has Dan Sundheim's D1 Capital Partners.

Representatives from Fidelity Investment Group declined to comment.

Statement:

This article is compiled based on third-party information and is intended for industry-related communication and learning purposes.

This article does not represent the views of 2FIRSTS and 2FIRSTS cannot confirm the truthfulness or accuracy of the content. The translation of this article is intended only for industry exchange and research.

Due to limitations in our ability to accurately translate, the translated text may differ in expression from the original article. Please refer to the original article for accuracy.

2FIRSTS maintains complete alignment with the Chinese government's positioning and stance on any domestic, cross-border including Hong Kong, Macau and Taiwan, or international issues.

The copyright of compiled information belongs to the original media and author. If there is any infringement, please contact us to have the content removed.